Replies to post #345596 on Avid Bioservices Inc (CDMO)

[north40000]

CDMO’s CEOs over the years, even recently, have distinguished between early and late stage customers in earnings conference calls. Pre-clinical or Phase 1-2a clinical trial customers were referred to as early stage that require less quantity of material for testing for results. Smaller size bioreactors would be used to produce that material. Conversely, late stage customers— those whose meds are in Phase 2b or Phase 3 clinical trials—often/always need material/med quantities that are sufficient for commercial sale once FDA approves an NDA. Larger bioreactors would produce that med.